Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?
|Title||Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease?|
|Publication Type||Journal Article|
|Year of Publication||2016|
|Authors||Ba M, Kong M, Li X, Ng KPin, Rosa-Neto P, Gauthier S|
Amyloid plaques are pathological hallmarks of Alzheimer's Disease (AD) and biomarkers such as cerebrospinal fluid (CSF) β-amyloid 1-42 (Aβ1-42) and amyloid positron emission tomographic (PET) imaging are important in diagnosing amyloid pathology in vivo. ɛ4 allele of the Apolipoprotein E gene (ApoE ɛ 4), which is a major genetic risk factor for late onset AD, is an important genetic biomarker for AD pathophysiology. It has been shown that ApoE ɛ 4 is involved in Aβ deposition and formation of amyloid plaques. Studies have suggested the utility of peripheral blood ApoE ɛ 4 in AD diagnosis and risk assessment. However it is still a matter of debate whether ApoE ɛ 4 status would improve prediction of amyloid pathology and represent a cost-effective alternative to amyloid PET or CSF Aβ in resource-limited settings in late onset AD. Recent research suggest that the mean prevalence of PET amyloid-positivity is 95% in ApoE ɛ 4-positive AD patients. This short review aims to provide an updated information on the relationship between ApoE ɛ 4 and amyloid biomarkers.
|Alternate Journal||Transl Neurodegener|
|PubMed Central ID||PMC5112745|